ArticleTherapeutic advances in medical oncology2026
Impact of TACE combined with targeted and immune therapy on liver function and prognosis in unresectable hepatocellular carcinoma patients: the significance of baseline albumin-bilirubin grade.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors (TTI) has emerged as a promising strategy for unresectable hepatocellular carcinoma (uHCC); however, its impact on liver function and the prognostic role of baseline albumin-bilirubin (ALBI) grade remain insufficiently defined. Objectives: To compare the effects of combined therapy and transarterial chemoembolization (TACE) alone on liver function in uHCC patients, and to evaluate the prognostic value of baseline ALBI grade. Design: This retrospective study enrolled uHCC patients treated with TTI or TACE alone between January 2018 and December 2023. Methods: The primary outcome was the time to progression of baseline ALBI grade, with secondary outcomes including overall survival (OS) and progression-free survival (PFS) of patients. Survival outcomes were analyzed using the Kaplan-Meier method. Results: A total of 162 patients (TTI group: 68; TACE alone group: 94) were included. The TTI group showed a significantly longer median time to progression of baseline ALBI grade than the TACE alone group (19.0 months vs 11.6 months, Conclusion: TTI therapy preserved liver function for a longer duration and achieved better survival outcomes than TACE alone in uHCC patients, particularly benefiting those with baseline ALBI grade 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.